Hepatitis B, ChronicPhase 2NCT04847440
A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
A Phase 2 study testing ATI-2173, Viread and AB-729 in people with Hepatitis B, Chronic and Hepatitis D, run by Antios Therapeutics, Inc at 2 sites in 2 countries.
Trial summary
This is a randomized, double-blinded, placebo-controlled, multi center, dose ranging study of safety and efficacy in both volunteers with chronic hepatitis B virus infection and in volunteers with hepatitis D virus coinfection. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Hepatitis B, Chronic, Hepatitis D
- What is being tested?
- ATI-2173, Viread and AB-729
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 30 Mar 2021to 1 Sep 2022
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ALL SUBJECTS:
- Provision of signed and dated informed consent form (ICF)
- Stated willingness to comply with all study procedures and availability for the duration of the study
- If female, meets one of the following criteria:
- Is of childbearing potential and agrees to use an acceptable contraceptive method. Acceptable contraceptive methods include:
- Abstinence from heterosexual intercourse from the first study drug administration through to at least 6 months after the last dose of the study drug or until completion of the study, whichever is longer
Show all 25Show fewer
- Use a systemic contraceptive or an intrauterine device (with or without hormones), from at least 28 days prior to the first study drug administration through to at least 6 months after the last dose of the study drug or until completion of the study, whichever is longer, with a male condom or a diaphragm/cervical cap plus spermicide from the first study drug administration through to at least 30 days after the last dose of the study drug or until completion of the study, whichever is longer
- Male partner vasectomized at least 6 months prior to the first study drug administration OR
- Male partner has had a vasectomy less than 6 months prior to dosing, and the female subject agrees to use an additional acceptable contraceptive method from the first study drug administration through to at least 6 months after the last dose of the study drug or until completion of the study, whichever is longer Or
- Is of non-childbearing potential, defined as surgically sterile (ie, has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or is in a postmenopausal state (ie, at least 1 year without menses without an alternative medical condition prior to the first study drug administration and follicle-stimulating hormone [FSH] levels within the normal ranges for postmenopausal state of the clinical site at screening)
- If male, meets one of the following criteria:
- Is able to procreate and agrees to use one of the accepted contraceptive regimens and not to donate sperm from the first study drug administration to at least 90 days after the last drug administration. Only for Cohort D: male subjects able to procreate must agree to use an accepted contraceptive regimen and not to donate sperm from the first study drug administration to at least 6 months after the last drug administration. An acceptable method of contraception includes one of the following:
- Abstinence from heterosexual intercourse
- Male condom with spermicide or male condom with a vaginal spermicide (gel, foam, or suppository) Or
- Is unable to procreate; defined as surgically sterile (ie, has undergone a vasectomy at least 6 months prior to the first study drug administration)
- Male or female aged at least 18 years but not older than 70 years
- Body mass index (BMI) within 18.0 kg/m2 to 35.0 kg/m2, inclusively
- Light-, non- or ex-smoker (A light smoker is defined as someone using 10.0 nicotine units or less per day for at least 90 days prior to the first study drug administration [refer to APPENDIX 7 for conversions of nicotine usage]. An ex-smoker is defined as someone who completely stopped using nicotine products for at least 6 months prior to the first study drug administration)
- Serum HBsAg positive at screening and at least 6 months prior to screening
- For Cohorts A, B and E only, serum HBeAg positive and HBV DNA ≥ 20,000 IU/mL, or serum HBeAg negative and HBV DNA ≥ 2,000 IU/mL at screening
- ALT and AST < 5 times the upper limit of normal (ULN) at screening and on the day prior to the first study drug administration (Day -1)
- SUBJECTS COINFECTED WITH CHRONIC HBV AND HDV ONLY:
- HDV RNA in serum ≥ 500 IU/mL at screening and evidence of HDV infection (HDVAb or HDV RNA) at least 6 months prior to screening
- SUBJECTS IN COHORT D ONLY:
- Serum HBsAg levels ≥ 100 IU/mL at screening
Who cannot join
- Female who is lactating at screening
- Female who is pregnant according to the pregnancy test at screening or prior to the first study drug administration
- History of significant hypersensitivity to clevudine, tenofovir disoproxil fumarate or any related products (including excipients of ATI-2173, tenofovir disoproxil fumarate, and the placebo) as well as severe hypersensitivity reactions (like angioedema) to any drugs
- History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
- Presence of clinically significant muscle disorders, myopathies or other forms of liver disease
- Presence of any clinically significant disease, as captured in the medical history or evidence of findings on the physical examination, vital sign assessment and/or ECG assessment, and that would otherwise exclude subject from eligibility in the context of all other listed inclusion and exclusion criteria, as determined by an Investigator
Show all 31Show fewer
- Presence of clinically significant ECG abnormalities at the screening visit, as defined by medical judgment
- Positive test result for alcohol and/or drugs of abuse at screening or prior to the first drug administration
- Any history of tuberculosis
- Active illicit drug use including, but not limited to, cocaine, heroin and methamphetamine (the use of cannabinoids is acceptable)
- Significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
- Use of amiodarone in the 28 days prior to the first study drug administration
- Presence or history of clinically significant gastrointestinal or kidney disease, or surgery that may affect drug bioavailability
- Cirrhosis of the liver as determined by one of the following:
- A score greater than F2 (or greater than F3 for HBV/HDV coinfected subjects) for liver fibrosis by FibroScan or FibroSure test within 6 months prior to screening or at the time of screening Or
- A score greater than F2 (or greater than F3 for HBV/HDV coinfected subjects) on liver biopsy within 12 months prior to screening or at the time of screening
- History of or known presence of hepatocellular carcinoma
- Acute infection or any other clinically significant illness within 14 days of Day 1 of the study
- History of organ transplantation
- Presence of uncontrolled hypertension
- Positive screening results to HIV Ag/Ab combo or hepatitis C virus tests
- Any other clinically significant abnormalities in laboratory test results at screening that would, in the opinion of an Investigator, increase the subject's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data
- Inclusion in another cohort for this clinical study
- Intake of an Investigational Product (IP) in the 28 days prior to the first study drug administration
- Donation of 50 mL or more of blood in the 28 days prior to the first study drug administration
- Donation of 500 mL or more of blood in the 56 days prior to the first study drug administration
- Previous approved or investigational treatment for HBV or HDV, including nucleoside therapy, other than treatment by tenofovir or interferon alpha. Prior treatment with tenofovir or interferon alpha must have been discontinued at least 6 months prior to Screening.
- SUBJECTS WITH CHRONIC HBV (COHORTS A, B, AND D):
- Positive screening results to HDV tests
- SUBJECTS IN COHORT D ONLY:
- History of significant hypersensitivity to excipients of AB-729, any siRNAs, or antisense oligonucleotides (ASOs)
Trial locations and contacts
2 sites in 2 countries.
2 sites in 2 countries
Moldova1 site
Republican Clinical Hospital "Timofei Mosneaga" Arensia EM Unit
Chisinau, Republic of Moldova
Ukraine1 site
Medical Center of Limited Liability Company "Harmoniya krasy"
Kyiv
About this study
Official title: A Phase 2A Randomized, Double-blinded, Placebo-controlled, Multicenter, Dose Ranging Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
This is a randomized, double-blinded, placebo-controlled, multi center, dose ranging study of safety and efficacy in both volunteers with chronic hepatitis B virus infection and in volunteers with hepatitis D virus coinfection. Volunteers will be administered multiple oral doses of ATI-2173 and assessed for safety and efficacy including blood tests to show how the body metabolizes and eliminates the investigational drug as well as how the drug effects the virus infection.
- Conditions
- Hepatitis B, Chronic, Hepatitis D
- Being tested
- ATI-2173, Viread, AB-729
- Medical subject headings
- Hepatitis B, Chronic, Hepatitis D
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ATI-2173Drug
ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
VireadDrug
Also called tenofovir disoproxil fumarate
Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
AB-729Drug
AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV
| Study group | Role | What they receive |
|---|---|---|
| ATI-2173 and Viread | Experimental | ATI-2173 + Tenofovir disoproxil fumarate (Viread) Receives: Drug: ATI-2173 |
| Placebo and Viread | Active comparator | ATI-2173 Placebo + Tenofovir disoproxil fumarate Receives: Drug: Viread |
| ATI-2173, Viread and AB-729 | Experimental | ATI-2173 + Tenofovir disoproxil fumarate (Viread) + AB-729 Receives: Drug: AB-729 |
| Placebo, Viread and AB-729 Placebo | Active comparator | ATI-2173 Placebo + Tenofovir disoproxil fumarate (Viread) + AB-729 Placebo Receives: Drug: Viread |
What is being measured
The primary outcome is the main question the study is designed to answer.
The percentage of subjects who experienced at least 1 treatment-emergent adverse event (TEAE)
Measured: Through study completion, an average of 1 year
The percentage of subjects who experienced at least one treatment emergent serious AE (SAE).
Measured: Through study completion, an average of 1 year
Percentage of subjects who experienced a treatment-emergent dose limiting toxicity (DLT)
Measured: Through study completion, an average of 1 year
Percentage of subjects who experienced at least one treatment emergent Grade 1, 2, 3, 4 or 5 laboratory abnormality
Measured: Through study completion, an average of 1 year
Percentage of subjects who discontinued study drug due to a TEAE
Measured: Through study completion, an average of 1 year
Alanine aminotransferase and aspartate aminotransferase levels versus time
Measured: Through study completion, an average of 1 year
Time to HBV viral load relapse in HBV-infected subjects
Measured: Through study completion, an average of 1 year
The reduction of HDV RNA on-treatment for HBV/HDV coinfected subjects
Measured: Through study completion, an average of 1 year
Secondary outcomes (33)
TE(max, HBV) up to Day 90 and through end of study with or without AB-729 or placebo + tenofovir
Measured: Through study completion, an average of 1 year
AUEC(HBV) up to Day 90 and through end of study with or without AB-729 of placebo + tenofovir
Measured: Through study completion, an average of 1 year
TE(max, HDV) up to Day 90 and through end of study
Measured: Through study completion, an average of 1 year
AUEC(HDV) up to Day 90 and through end of study
Measured: Through study completion, an average of 1 year
Baseline-adjusted maximal reduction in HBV DNA viral load (Emax,HBV) through 6 months after end of treatment following ATI-2173 + tenofovir (with or without AB-729) or placebo + tenofovir for 90 days in HBV-infected and HBV/HDV coinfected subjects
Measured: Through study completion at 6 months follow up
Baseline-adjusted maximal reduction in HDV RNA viral load (Emax,HDV) through 6 months after end of treatment following ATI-2173 + tenofovir or placebo + tenofovir for 90 days in HBV/HDV coinfected subjects
Measured: Through study completion at 6 months follow up
Cmax of ATI-2173, clevudine, tenofovir and M1 in plasma
Measured: Through Day 120
Tmax of ATI-2173, clevudine, tenofovir and M1 in plasma
Measured: Through Day 120
Ctrough of ATI-2173, clevudine, tenofovir and M1 in plasma
Measured: Through Day 120
Ctau of ATI-2173, clevudine, tenofovir and M1 in plasma
Measured: Through Day 120
AUC0-24 of ATI-2173, clevudine, tenofovir and M1 in plasma
Measured: Through Day 120
T1/2 of ATI-2173, clevudine, tenofovir and M1 in plasma
Measured: Through Day 120
RAC(Cmax) of ATI-2173, clevudine, tenofovir and M1 in plasma
Measured: Through Day 120
RAC(AUC) of ATI-2173, clevudine, tenofovir and M1 in plasma
Measured: Through Day 120
Correlation between individual Day 90 clevudine and tenofovir Cmin and Emax,HBV or Emax, HDV of viral load
Measured: Through Day 90
Proportion of subjects with HBV SVR6 by treatment arm
Measured: Through study completion, an average of 1 year
Proportion of subjects with HDV SVR6 by treatment arm (HBV/HDV coinfected subjects only)
Measured: Through study completion, an average of 1 year
Proportion of subjects by treatment arm with HBV SVR12, SVR18, and SVR24
Measured: Through study completion, an average of 1 year
Proportion of subjects by treatment arm with HDV SVR12, SVR18, and SVR24 (HBV/HDV coinfected subjects only)
Measured: Through study completion, an average of 1 year
Proportion of subjects by treatment arm with on-treatment ALT flares
Measured: Through Day 90
Proportion of subjects by treatment arm with off-treatment ALT flares, with no on-treatment ALT flares by treatment arm
Measured: From Day 90 through end of study, an average of 1 year
HBV DNA slope off-treatment
Measured: Through end of study, an average of 1 year
Effect on HBV pgRNA in subjects who reach SVR6 as measured by percentage of subjects by validated assay
Measured: Through end of study, an average of 1 year
HBV pgRNA at end of treatment by treatment arm
Measured: Through Day 90
Effect on HBsAg in subjects who reach HBV SVR6 as measured by percentage of subjects by validated assay
Measured: Through end of study, an average of 1 year
T(Emax,HBV) through 6 months after end of treatment following ATI-2173 + tenofovir for 90 days in HBV-infected subjects and in HBV/HDV coinfected subjects
Measured: Through end of study, an average of 1 year
AUEC(HBV) through 6 months after end of treatment following ATI-2173 + tenofovir for 90 days in HBV-infected subjects and in HBV/HDV coinfected subjects
Measured: Through end of study, an average of 1 year
T(Emax,HBV) through 6 months after end of treatment following ATI-2173 + tenofovir for 90 days in HBV/HDV coinfected subjects
Measured: Through end of study, an average of 1 year
AUEC(HDV) through 6 months after end of treatment following ATI-2173 + tenofovir for 90 days in HBV/HDV coinfected subjects
Measured: Through end of study, an average of 1 year
Change from baseline in HBsAg, HBV pgRNA, and HBcrAg at end of treatment and SVR6 in HBV-infected and in HBV/HDV coinfected subjects by treatment arm
Measured: Through end of study, an average of 1 year
Reduction from baseline in HBsAg, HBV pgRNA, and HBcrAg following ATI-2173 + tenofovir (with or without AB-729) or placebo + tenofovir for 90 days in HBV-infected and HBV/HDV coinfected subjects
Measured: Through end of study, an average of 1 year
Correlation between individual time to viral load relapse and Day 90 clevudine and/or tenofovir Cmin and AUC
Measured: Through Day 90
Correlation between SVR6 and Day 90 clevudine and/or tenofovir Cmin and AUC
Measured: Through Day 90
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Apr 2021
- Study start30 Mar 2021
- Primary completion1 Sep 2022
- Study completion1 Sep 2022
Why it stopped: Terminated by the Sponsor
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatitis B, ChronicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Antios Therapeutics, Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04847440
- Sponsor's protocol ID
- ANTT201
- Status last verified
- Nov 2022
- First submitted
- 6 Apr 2021
- Last updated
- 18 Nov 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2A Randomized, Double-blinded, Placebo-controlled, Multicenter, Dose Ranging Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
- ClinicalTrials.gov ID
- NCT04847440
- Acronym / sponsor ID
- ANTT201
- Conditions
- Hepatitis B, Chronic, Hepatitis D
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Terminated by the Sponsor
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Antios Therapeutics, IncIndustry (pharma, biotech, devices)
- Study start
- 30 Mar 2021 (actual)
- Primary completion
- 1 Sep 2022 (actual)
- Study completion
- 1 Sep 2022 (actual)
- First posted
- 19 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, double-blinded, placebo-controlled, multi center, dose ranging study of safety and efficacy in both volunteers with chronic hepatitis B virus infection and in volunteers with hepatitis D virus coinfection. Volunteers will be administered multiple oral doses of ATI-2173 and assessed for safety and efficacy including blood tests to show how the body metabolizes and eliminates the investigational drug as well as how the drug effects the virus infection.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| ATI-2173 and Viread | Experimental | Drug: ATI-2173ATI-2173 + Tenofovir disoproxil fumarate (Viread) |
| Placebo and Viread | Active comparator | Drug: VireadATI-2173 Placebo + Tenofovir disoproxil fumarate |
| ATI-2173, Viread and AB-729 | Experimental | Drug: AB-729ATI-2173 + Tenofovir disoproxil fumarate (Viread) + AB-729 |
| Placebo, Viread and AB-729 Placebo | Active comparator | Drug: VireadATI-2173 Placebo + Tenofovir disoproxil fumarate (Viread) + AB-729 Placebo |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (25 listed)
- Provision of signed and dated informed consent form (ICF)
- Stated willingness to comply with all study procedures and availability for the duration of the study
- If female, meets one of the following criteria:
- If male, meets one of the following criteria:
- Male or female aged at least 18 years but not older than 70 years
Key exclusion criteria (31 listed)
- Female who is lactating at screening
- Female who is pregnant according to the pregnancy test at screening or prior to the first study drug administration
- History of significant hypersensitivity to clevudine, tenofovir disoproxil fumarate or any related products (including excipients of ATI-2173, tenofovir disoproxil fumarate, and the placebo) as well as severe hypersensitivity reactions (like angioedema) to any drugs
- History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
- Presence of clinically significant muscle disorders, myopathies or other forms of liver disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ATI-2173ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus. | Drug | ATI-2173 and Viread |
| VireadAlso: tenofovir disoproxil fumarateViread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus. | Drug | Placebo and Viread, Placebo, Viread and AB-729 Placebo |
| AB-729AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV | Drug | ATI-2173, Viread and AB-729 |
Primary outcome
The percentage of subjects who experienced at least 1 treatment-emergent adverse event (TEAE)
Time frame: Through study completion, an average of 1 year
The percentage of subjects who experienced at least one treatment emergent serious AE (SAE).
Time frame: Through study completion, an average of 1 year
Percentage of subjects who experienced a treatment-emergent dose limiting toxicity (DLT)
Time frame: Through study completion, an average of 1 year
Percentage of subjects who experienced at least one treatment emergent Grade 1, 2, 3, 4 or 5 laboratory abnormality
Time frame: Through study completion, an average of 1 year
Percentage of subjects who discontinued study drug due to a TEAE
Time frame: Through study completion, an average of 1 year
Alanine aminotransferase and aspartate aminotransferase levels versus time
Time frame: Through study completion, an average of 1 year
Time to HBV viral load relapse in HBV-infected subjects
Time frame: Through study completion, an average of 1 year
The reduction of HDV RNA on-treatment for HBV/HDV coinfected subjects
Time frame: Through study completion, an average of 1 year
33 secondary outcomes
TE(max, HBV) up to Day 90 and through end of study with or without AB-729 or placebo + tenofovir
Time frame: Through study completion, an average of 1 year
AUEC(HBV) up to Day 90 and through end of study with or without AB-729 of placebo + tenofovir
Time frame: Through study completion, an average of 1 year
TE(max, HDV) up to Day 90 and through end of study
Time frame: Through study completion, an average of 1 year
AUEC(HDV) up to Day 90 and through end of study
Time frame: Through study completion, an average of 1 year
Baseline-adjusted maximal reduction in HBV DNA viral load (Emax,HBV) through 6 months after end of treatment following ATI-2173 + tenofovir (with or without AB-729) or placebo + tenofovir for 90 days in HBV-infected and HBV/HDV coinfected subjects
Time frame: Through study completion at 6 months follow up
Baseline-adjusted maximal reduction in HDV RNA viral load (Emax,HDV) through 6 months after end of treatment following ATI-2173 + tenofovir or placebo + tenofovir for 90 days in HBV/HDV coinfected subjects
Time frame: Through study completion at 6 months follow up
Cmax of ATI-2173, clevudine, tenofovir and M1 in plasma
Time frame: Through Day 120
Tmax of ATI-2173, clevudine, tenofovir and M1 in plasma
Time frame: Through Day 120
Ctrough of ATI-2173, clevudine, tenofovir and M1 in plasma
Time frame: Through Day 120
Ctau of ATI-2173, clevudine, tenofovir and M1 in plasma
Time frame: Through Day 120
AUC0-24 of ATI-2173, clevudine, tenofovir and M1 in plasma
Time frame: Through Day 120
T1/2 of ATI-2173, clevudine, tenofovir and M1 in plasma
Time frame: Through Day 120
RAC(Cmax) of ATI-2173, clevudine, tenofovir and M1 in plasma
Time frame: Through Day 120
RAC(AUC) of ATI-2173, clevudine, tenofovir and M1 in plasma
Time frame: Through Day 120
Correlation between individual Day 90 clevudine and tenofovir Cmin and Emax,HBV or Emax, HDV of viral load
Time frame: Through Day 90
Proportion of subjects with HBV SVR6 by treatment arm
Time frame: Through study completion, an average of 1 year
Proportion of subjects with HDV SVR6 by treatment arm (HBV/HDV coinfected subjects only)
Time frame: Through study completion, an average of 1 year
Proportion of subjects by treatment arm with HBV SVR12, SVR18, and SVR24
Time frame: Through study completion, an average of 1 year
Proportion of subjects by treatment arm with HDV SVR12, SVR18, and SVR24 (HBV/HDV coinfected subjects only)
Time frame: Through study completion, an average of 1 year
Proportion of subjects by treatment arm with on-treatment ALT flares
Time frame: Through Day 90
Proportion of subjects by treatment arm with off-treatment ALT flares, with no on-treatment ALT flares by treatment arm
Time frame: From Day 90 through end of study, an average of 1 year
HBV DNA slope off-treatment
Time frame: Through end of study, an average of 1 year
Effect on HBV pgRNA in subjects who reach SVR6 as measured by percentage of subjects by validated assay
Time frame: Through end of study, an average of 1 year
HBV pgRNA at end of treatment by treatment arm
Time frame: Through Day 90
Effect on HBsAg in subjects who reach HBV SVR6 as measured by percentage of subjects by validated assay
Time frame: Through end of study, an average of 1 year
T(Emax,HBV) through 6 months after end of treatment following ATI-2173 + tenofovir for 90 days in HBV-infected subjects and in HBV/HDV coinfected subjects
Time frame: Through end of study, an average of 1 year
AUEC(HBV) through 6 months after end of treatment following ATI-2173 + tenofovir for 90 days in HBV-infected subjects and in HBV/HDV coinfected subjects
Time frame: Through end of study, an average of 1 year
T(Emax,HBV) through 6 months after end of treatment following ATI-2173 + tenofovir for 90 days in HBV/HDV coinfected subjects
Time frame: Through end of study, an average of 1 year
AUEC(HDV) through 6 months after end of treatment following ATI-2173 + tenofovir for 90 days in HBV/HDV coinfected subjects
Time frame: Through end of study, an average of 1 year
Change from baseline in HBsAg, HBV pgRNA, and HBcrAg at end of treatment and SVR6 in HBV-infected and in HBV/HDV coinfected subjects by treatment arm
Time frame: Through end of study, an average of 1 year
Reduction from baseline in HBsAg, HBV pgRNA, and HBcrAg following ATI-2173 + tenofovir (with or without AB-729) or placebo + tenofovir for 90 days in HBV-infected and HBV/HDV coinfected subjects
Time frame: Through end of study, an average of 1 year
Correlation between individual time to viral load relapse and Day 90 clevudine and/or tenofovir Cmin and AUC
Time frame: Through Day 90
Correlation between SVR6 and Day 90 clevudine and/or tenofovir Cmin and AUC
Time frame: Through Day 90
Results and safety
The study was stopped early (reason given: Terminated by the Sponsor). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2022.
- Individual participant dataSharing planned: No
Related trials for Hepatitis B, Chronic
Active, not recruitingPhase 2
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
Chronic Hepatitis B Virus Infection, Hepatitis B
RecruitingObservational study
Evaluation of Patients With Liver Disease
Hepatitis D, Hepatitis C
Active, not recruitingPhase 2
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
Hepatitis B
Active, not recruitingPhase 2
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
Hepatitis B
Enrolling by invitationPhase 1
A Phase I Clinical Trial of CPU-YL01 Injection in Patients With Chronic Hepatitis B.
Chronic Hepatitis B
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing ATI-2173, Viread and AB-729 in people with Hepatitis B, Chronic and Hepatitis D, run by Antios Therapeutics, Inc at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 25 inclusion and 31 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 18 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Moldova, Ukraine. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Terminated by the Sponsor). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The percentage of subjects who experienced at least 1 treatment-emergent adverse event (TEAE) (time frame: Through study completion, an average of 1 year). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2022.